4747.TWO Johnson Chemical Pharmaceutical Works Co Ltd
- Market cap
- TWD 1.96B
- P/E
- 22.0x
- P/B
- 1.18x
- ROE
- 8.8%
- Dividend yield
- 4.00%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4747.TWO undervalued?
Graham number4747.TWO trades 7.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Johnson Chemical Pharmaceutical Works Co Ltd fundamental analysis
No fundamental analysis for Johnson Chemical Pharmaceutical Works Co Ltd yet.
Johnson Chemical Pharmaceutical Works Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Johnson Chemical Pharmaceutical Works Co Ltd
Johnson Chemical Pharmaceutical Works Co., Ltd. manufactures, imports, and sells pharmaceutical ingredients, materials and products in Taiwan. The company manufactures drugs in a variety of forms, such as solid dosage form, capsule, tablet, and powder and granule, as well as nasal spray forms. It offers its products in various therapeutic areas, including central nervous system, respiratory, cardiovascular, gastrointestinal, endocrine system, vitamins, anti-inflammatory, cou…
Full company profileJohnson Chemical Pharmaceutical Works Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Johnson Chemical Pharmaceutical Works Co Ltd annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 392M | 395M | 412M | 425M | 424M | 411M | 495M | 607M | 611M | 570M | 586M |
| Gross Profit | 179M | 169M | 177M | 191M | 192M | 172M | 204M | 245M | 248M | 228M | 226M |
| Operating Income | 72.5M | 66.4M | 68.8M | 78.9M | 75.5M | 62.3M | 82.7M | 98.9M | 98.0M | 73.1M | 62.4M |
| EBITDA | - | 76.9M | 79.3M | 93.6M | 90.6M | 78.3M | 101M | 127M | 133M | 87.5M | 201M |
| Net Income | 63.4M | 60.0M | 57.3M | 64.5M | 63.6M | 49.1M | 64.9M | 79.7M | 84.1M | 53.5M | 154M |
| EPS | - | 2.00 | 1.91 | 2.15 | 2.12 | 1.64 | 2.16 | 0.91 | 0.94 | 0.59 | 1.69 |
| Balance Sheet | |||||||||||
| Total Assets | 956M | 931M | 937M | 952M | 1.10B | 1.03B | 1.04B | 1.99B | 1.97B | 2.09B | 2.56B |
| Total Liabilities | 123M | 95.6M | 100M | 104M | 240M | 179M | 168M | 321M | 261M | 384M | 820M |
| Shareholders' Equity | 832M | 835M | 837M | 848M | 858M | 848M | 872M | 1.67B | 1.70B | 1.71B | 1.74B |
| Cash & Short-term Investments | 333M | 306M | 310M | 310M | 296M | 202M | 168M | 1.09B | 1.07B | 1.05B | 262M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 68.2M | 39.9M | 68.2M | 71.5M | 71.8M | 52.3M | 89.7M | 137M | 62.9M | 71.7M | -12.6M |
| Capital Expenditure | 95.4M | 3.67M | 7.33M | 15.1M | 162M | 37.3M | 59.7M | 33.1M | 13.2M | 64.0M | 40.7M |
| Free Cash Flow | - | 36.2M | 60.8M | 56.4M | -90.4M | 15.1M | 30.0M | 104M | 49.7M | 7.66M | -53.3M |
| Ratios | |||||||||||
| ROE | 7.6% | 7.2% | 6.8% | 7.6% | 7.4% | 5.8% | 7.4% | 4.8% | 4.9% | 3.1% | 8.8% |
| ROA | 6.6% | 6.4% | 6.1% | 6.8% | 5.8% | 4.8% | 6.2% | 4.0% | 4.3% | 2.6% | 6.0% |
| Net Profit Margin | 16.2% | 15.2% | 13.9% | 15.2% | 15.0% | 11.9% | 13.1% | 13.1% | 13.8% | 9.4% | 26.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Johnson Chemical Pharmaceutical Works Co Ltd dividends
- Dividend yield
- 4.00%
- Forward dividend
- 0.53 TWD
- Payout ratio
- 147.0%
- Ex-dividend date
- Jul 6, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 78.6M | 0.87 | 147.0% |
| 2024 | TWD 67.3M | 0.75 | 80.0% |
| 2023 | TWD 60.0M | 0.69 | 75.3% |
| 2022 | TWD 43.5M | 1.45 | 67.1% |
| 2021 | TWD 57.6M | 1.92 | 117.4% |
| 2020 | TWD 54.0M | 1.80 | 85.0% |
| 2019 | TWD 49.5M | 1.65 | 76.8% |
| 2018 | TWD 54.0M | 1.80 | 94.3% |
| 2017 | TWD 57.0M | 1.90 | 95.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2000:1000 on Aug 20, 2026.
Who owns Johnson Chemical Pharmaceutical Works Co Ltd
- Insiders 55.97%
- Institutions 0.07%
- Public & others 43.97%
- Shares outstanding 90.9M
- Free float 46.6M
Johnson Chemical Pharmaceutical Works Co Ltd company profile
- Company name
- Johnson Chemical Pharmaceutical Works Co Ltd
- Ticker
- 4747.TWO
- ISIN
- TW0004747001
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 188
- Fiscal year end
- December
- Address
- No. 77 and No.79, Sanhe Road, New Taipei City, Taiwan, 241
- Phone
- 886 2 2989 4756
- Website
- jcpjohnson.com.tw
About Johnson Chemical Pharmaceutical Works Co Ltd
Johnson Chemical Pharmaceutical Works Co., Ltd. manufactures, imports, and sells pharmaceutical ingredients, materials and products in Taiwan. The company manufactures drugs in a variety of forms, such as solid dosage form, capsule, tablet, and powder and granule, as well as nasal spray forms. It offers its products in various therapeutic areas, including central nervous system, respiratory, cardiovascular, gastrointestinal, endocrine system, vitamins, anti-inflammatory, cough and cold, pain reliever, etc. The company was founded in 1959 and is based in New Taipei City, Taiwan.
Johnson Chemical Pharmaceutical Works Co Ltd management
4- Mr. Baixiong HuangChairman & CEO
- Ms. Yixiu ChenFinance Director
- Mr. Weike LinSales Director
- Mr. Peter LinChief Research Officer